Mavtac Forte Ointment contains Tacrolimus 0.1% w/w, a potent immunomodulatory agent primarily indicated for the treatment of moderate to severe atopic dermatitis in patients who are unresponsive to conventional therapies or when those therapies are contraindicated. Tacrolimus acts by inhibiting calcineurin, thereby suppressing T-lymphocyte activation and the subsequent release of pro-inflammatory cytokines, which play a critical role in the pathogenesis of inflammatory skin conditions. The ointment formulation facilitates effective topical delivery, ensuring targeted immunosuppression with minimal systemic absorption. Mavtac Forte Ointment is applied thinly to the affected areas twice daily, with treatment duration tailored according to clinical response and disease severity. It is essential to avoid occlusive dressings unless directed by a healthcare professional. Common adverse effects include transient burning or pruritus at the application site, which typically diminish with continued use. Long-term safety beyond one year has not been established; therefore, periodic evaluation by a healthcare provider is recommended. Mavtac Forte Ointment should be used with caution in patients with compromised immune systems or a history of malignancy. It is contraindicated in individuals with hypersensitivity to tacrolimus or any ointment components. Patient education on appropriate use and avoidance of sun exposure during treatment is advised to minimize potential risks.